Erudio Healtherudio.com
Drug
Belzutifan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying belzutifan: LITESPARK-011. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 13 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| LITESPARK-011 NCT04586231 · Merck Sharp & Dohme LLC | advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy | Phase 3 | 1,422 | 235 | Deep | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LITESPARK-005 NCT04195750 · Merck Sharp & Dohme LLC DeepView → | Not given | Phase 3 | Deep | View | |||
| LITESPARK-022 NCT05239728 · Merck Sharp & Dohme LLC DeepView → | adjuvant clear cell renal cell carcinoma post nephrectomy | Phase 3 | Deep | View | |||
| LITESPARK-012 NCT04736706 · Merck Sharp & Dohme LLC DeepView → | first-line advanced clear cell renal cell carcinoma | Phase 3 | Deep | View | |||
| LITESPARK-004 NCT03401788 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) DeepView → | von Hippel-Lindau disease-associated renal cell carcinoma | Phase 2 | Deep | View | |||
| LITESPARK-013 NCT04489771 · Merck Sharp & Dohme LLC DeepView → | advanced clear cell renal cell carcinoma | Phase 2 | Deep | View | |||
| KEYNOTE-365 NCT02861573 · Merck Sharp & Dohme LLC DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| LITESPARK-024 NCT05468697 · Merck Sharp & Dohme LLC StandardView → | advanced renal cell carcinoma | Phase 1/Phase 2 | Standard | View | |||
| LITESPARK-003 NCT03634540 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) FocusedView → | advanced clear cell renal cell carcinoma | Phase 2 | Focused | View | |||
| LITESPARK-001 NCT02974738 · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) FocusedView → | advanced solid tumors | Phase 1 | Focused | View | |||
| KEYMAKER-U03 NCT04626518 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| KEYMAKER-U03 NCT04626479 · Merck Sharp & Dohme LLC FocusedView → | first-line advanced clear-cell renal cell carcinoma | Phase 1/Phase 2 | Focused | View | |||
| NCT04924075 NCT04924075 · Merck Sharp & Dohme LLC FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT06234605 NCT06234605 · HiberCell, Inc. FocusedView → | locally advanced or metastatic renal cell carcinoma | Phase 1 | Focused | View | |||